Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Monitoring neuromuscular blockade in the ICU: a reliability look

Official title: Monitoring of Neuromuscular Blockade in the Intensive Care Unit: a Reliability Study

Run by Centre Hospitalier Intercommunal Aix-Pertuis · NCT07741851 · Data updated 2026-11-12

This study tests how reliably neuromuscular blockade monitoring works in adult ICU patients who have been given neuromuscular blocking drugs.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment160 (estimated)
SponsorCentre Hospitalier Intercommunal Aix-Pertuis
Academic / other
Locations1 site (Aix-en-Provence)
StatusRecruiting
StartedApril 2, 2026
Main results expectedJanuary 2027
Study endsJanuary 2027
Registry record updatedAugust 3, 2026
Trial IDNCT07741851 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adult ICU patients who have received neuromuscular blocking agents for at least 24 hours and consent (or family consent) has been obtained.

Probably not a fit

Patients not requiring prolonged neuromuscular blockade or those with contraindications to monitoring methods may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study evaluates the reliability of neuromuscular blockade monitoring in adults admitted to the ICU and treated with neuromuscular blocking agents. It includes assessments of measurements at the ulnar nerve with TOF stimulation and tracks safety by monitoring for adverse events such as respiratory effort or patient-ventilator asynchrony over 24-hour periods. The trial discusses how monitoring methods align with clinical context and existing guidelines, and it explores potential anomalies when neuromuscular blockade is present or absent. The study is conducted at a single center, led by Centre Hospitalier Intercommunal Aix-Pertuis, and focuses on practical monitoring in routine ICU care. Overall, it aims to determine whether current monitoring approaches provide reliable information across typical ICU scenarios.

Why it matters

Potential benefit: If successful, clinicians may have greater confidence in neuromuscular blockade monitoring in the ICU, potentially improving safety and patient comfort during mechanical ventilation.

How similar studies have gone: Previous guidance supports intraoperative neuromuscular blockade monitoring; this study extends reliability assessment to the ICU setting with a focus on safety.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adult patients
* Patients admitted to the intensive care unit who have been receiving neuromuscular blocking agents for at least 24 hours during their stay - Consent obtained from the patient or emergency consent obtained from family members
* Patients covered by the French social security system, regardless of the specific plan

Exclusion Criteria:

* Patients who have already been exposed to prolonged neuromuscular blockade or who have been receiving continuous neuromuscular blockade for less than 24 hours
* Allergy to neuromuscular blocking agents
* Patients with a neurological condition that alters the interpretation of neuromuscular blockade or contraindicates the use of neuromuscular blocking agents
* Patients enrolled in an interventional study
* Patients who object to the collection of their medical data for this study
* Patients under the age of 18
* Patients deprived of their liberty, under guardianship, or under conservatorship
* Pregnant or breastfeeding women

Where it's running

  • Centre Hospitalier Intercommunal Aix-Pertuis
    Aix-en-Provence, France
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.